Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SB-204269 SmithKline Beecham.

F Crespi1

  • 1Glaxo Wellcome SpA, Pharmacology Department, Via Fleming 4, 37100 Verona, Italy. FC20377@ggr.co.uk

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lifetime measurements of the neutron-rich N = 30 isotones 50Ca and 51Sc: orbital dependence of effective charges in the fp shell.

Physical review letters·2009
Same author

Apamin increases 5-HT cell firing in raphe dorsalis and extracellular 5-HT levels in amygdala: a concomitant in vivo study in anesthetized rats.

Brain research·2009
Same author

Giant dipole resonance in the hot and thermalized 132Ce nucleus: damping of collective modes at finite temperature.

Physical review letters·2006
Same author

Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.

Experimental brain research·2002
Same author

Can voltammetry measure nitrogen monoxide (NO) and/or nitrites?

Journal of neuroscience methods·2001
Same author

Electrochemical evidence that lacidipine stimulates release of nitrogen monoxide in rat aorta.

Neuroscience letters·2001
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

SB-204269 is a novel anticonvulsant agent in development for epilepsy. Its unique mechanism of action does not involve ATP-sensitive potassium channels, distinguishing it from related compounds.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • SB-204269 is an anticonvulsant agent developed by SmithKline Beecham.
  • It is structurally related to cromakalim, a benzopyran ATP-sensitive potassium channel (KATP) opener, but possesses opposite stereochemistry.

Purpose of the Study:

  • To investigate the anticonvulsant properties and mechanism of action of SB-204269.
  • To determine if SB-204269's activity involves ATP-sensitive potassium channels.

Main Methods:

  • Pre-clinical studies evaluating anticonvulsant activity.
  • Binding assays to assess affinity for ATP-sensitive potassium channels.
  • Stereochemical analysis and comparison with enantiomer SB-204268.

Main Results:

  • SB-204269 demonstrated anticonvulsant activity.

Related Experiment Videos

  • No significant affinity for the ATP-sensitive potassium channel binding site was observed for SB-204269.
  • The opposite enantiomer, SB-204268, showed no anticonvulsant activity.

    • Conclusions:

    • SB-204269 represents a mechanistically novel anticonvulsant agent.
    • The mechanism of action of SB-204269 is not believed to involve ATP-sensitive potassium channels.